Akero Therapeutics Inc (AKRO)

AKRO Crappy Phase 2 Data makes the King Madrigal more valuable!

AKRO

Should see the 60's! core holding in my IRA was $7.00 not that long ago need the foresight to really hit these home runs!

A market that could grow to $108.4 Billion globally by 2030. MASH 3.7 Billion Market cap. This is IV route drug. Looked in my Ira bought a chunk at $14.00 a few years ago.


AKRO

AKRO: And now it's, AT THE BREAKOUT.

https://markets.businessinsider.com/news/stocks/attention-longterm-shareholders-of-akero-therapeutics-inc.-akro-grabar-law-office-investigates-claims-on-your-behalf-1033786530
Philadelphia, Pennsylvania--(Newsfile Corp. - September 20, 2024) - If you are a shareholder who has held Akero Therapeutics, Inc. (NASDAQ: AKRO) shares since prior to September 13, 2022, and would like to learn more about the investigation and your rights, please visit https://grabarlaw.com/the-latest/akero-shareholder-investigation/

AKRO near a break out

Starter position down here, mid $15’s…don’t follow company, but sell side folks seem
To give them more time to develop
Readouts in q1/2024…also:


Akero's cash, cash equivalents and short-term and long-term marketable securities for the period ended June 30, 2023 were $658.9 million.
Akero believes that its current cash, cash equivalents, short-term and long-term marketable securities will be sufficient to fund its current operating plan into 2026.

Not so much now....

Nice bounce this morning

Profit taking :__:)

WOW

$54

Hit $50.01 today!

Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
December 21 2022 - 04:01PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced that it has completed enrollment of the Phase 2b SYMMETRY main study evaluating efruxifermin (EFX) for the treatment of non-alcoholic steatohepatitis (NASH), in patients with compensated cirrhosis fibrosis stage 4 (F4). Enrollment is also complete for the expansion cohort, known as Cohort D, evaluating EFX in combination with GLP-1 therapy in patients with fibrosis stage 1-3 (F1-F3) and Type 2 Diabetes Mellitus (T2D).
“We are encouraged by the strength of our EFX data to date, including histology data from a Phase 2a proof-of-concept study in patients with cirrhosis due to NASH, and believe EFX has the potential to show favorable histology results in the SYMMETRY main study despite other investigational drugs having shown limited efficacy,” said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. “We look forward to reporting SYMMETRY data later next year as we evaluate EFX’s potential to slow or reverse progression of cirrhosis.”

The Phase 2b SYMMETRY main study is a multicenter, randomized, double-blind, placebo-controlled, clinical trial in biopsy-confirmed NASH patients with compensated cirrhosis (F4, Child-Pugh class A). One hundred eighty-two patients have been randomized to receive once-weekly subcutaneous dosing of 28mg EFX, 50mg EFX, or placebo. The primary endpoint for the trial is fibrosis regression after 36 weeks treatment. Secondary measures include change from baseline in liver enzymes, liver fat, lipoproteins, glycemic control, and body weight at 36 weeks, as well as evaluation of safety and tolerability. To provide additional safety data from long-term follow up, patients will continue to receive EFX or placebo from 36 to 96 weeks.

The primary goal of the 12-week Cohort D expansion, in which 32 patients have been randomized, is to assess safety and tolerability of EFX compared to placebo when added to an existing GLP-1 receptor agonist in patients with T2D and F1-F3 liver fibrosis due to NASH. Demonstrating that EFX could accelerate NASH resolution and reversal of fibrosis among those patients already on GLP-1 therapy would help address an important unmet medical need.

Consistent with prior guidance, results from the Cohort D expansion cohort are expected in the second quarter of 2023, while results from the main study remain on track to be reported in the fourth quarter of 2023.

Following designation of EFX as a Breakthrough Therapy by the FDA, an End-of-Phase 2 meeting has been scheduled for March 2023 to review the HARMONY F2/3 data as well as the proposed Ph3 clinical program.

About NASH
NASH (non-alcoholic steatohepatitis) is a serious form of NAFLD (non-alcoholic fatty liver disease) that is estimated to affect 17 million Americans. NASH is characterized by an excessive accumulation of fat in the liver that causes stress and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death. There are no approved treatments for the condition and NASH is a leading cause of liver transplants in the US and Europe.

About Efruxifermin
Efruxifermin (EFX), formerly known as AKR-001, is Akero’s lead product candidate for NASH, currently being evaluated in the ongoing Phase 2b HARMONY and SYMMETRY studies. EFX is designed to reduce liver fat and inflam

Nov 16 2022 45.74 0.96 2.14% 44.93 46.495 44.59 537,851

i totally missed out but CONGRAT$$$ to any who made profit$$$

G2G. We hit an all-time high today 0f $45. Still have half my holdings. Looking for $50
How have you been doing?

Anytime MR McDoogi. Check this form 4. the insider bought at 0.65 and look what price he got out. https://ih.advfn.com/stock-market/NASDAQ/akero-therapeutics-AKRO/stock-news/89227914/statement-of-changes-in-beneficial-ownership-4

Thank you so much for ALL the amazing tips subs brother!!!

What an utterly A M A Z I N G past 4+ months & counting>>>$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

wow nice day........subs


you
doog
BBW
and me on the same board

wtfreak

We closed @ $38.27. I don't have time for that sabbatical but when I do I won't really be on a long vacation because we can't sleep and miss gems like this. Right MR McDoog?

Now they want to do a 175 mil PP. NEXT!

YEAR RANGE $7.52 - $29.78 PREVIOUS CLOSE $12.27

I like the saying if it's not broken don't try to fix it. The OTC market in general is being pissed on.

Ever since June 1st you've been beyond belief on FIRE thank you soooooooooo much brotha>>>$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

If you get up at 6 am est time you can find these monsters before they run. Best time for bed is 4 pm est lol :)

Ding ding ding ding ding!!! Another 1 for the winners circle subs buddy ty!!!

In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks
September 13 2022 - 06:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today released topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), fibrosis stage 2 or 3 (F2-F3). The study met its primary endpoint for both the 50mg and 28mg EFX dose groups, with 41% and 39% of EFX-treated patients, respectively, experiencing at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 24, compared with 20% for the placebo arm.
The study also met a key secondary endpoint with 76% and 47% of patients treated with 50mg and 28mg, respectively, achieving NASH resolution without worsening of fibrosis, compared with 15% for placebo. In addition, 41% and 29% of patients treated with 50mg and 28mg, respectively, achieved both endpoints (NASH resolution and fibrosis improvement ≥1 stage), compared with 5% for placebo.

“The statistically significant histological improvements observed in the HARMONY study are among the strongest efficacy results reported in NASH to date and, together with strong results in secondary endpoints, show that EFX has the potential to treat the core facets of NASH,” said Stephen Harrison, M.D., medical director of Pinnacle Clinical Research and the HARMONY study’s principal investigator. “I believe the magnitude and general consistency of results observed across the Phase 2a BALANCED and Phase 2b HARMONY studies increase the probability of success in Phase 3 and position EFX to potentially be a foundational monotherapy for patients with NASH.”

Patients in the HARMONY study exhibited characteristics of patients at high risk of disease progression. The mean body weight across dose groups was approximately 105 kilograms. Roughly 70% of patients across dose groups had Type 2 diabetes as well as NASH. Approximately twice as many patients in the HARMONY study had fibrosis stage 3 (66%) as fibrosis stage 2 (34%). Despite these indicators of more advanced disease, the study also demonstrated statistically significant effects in multiple secondary endpoints in both dose groups, including improvements in liver fat, liver enzymes, non-invasive fibrosis markers, HbA1c, lipoproteins, and body weight. Treatment with EFX was generally well-tolerated, with a tolerability profile comparable to that observed in Akero’s Phase 2a BALANCED study.

“We believe today’s results from the HARMONY study are an important milestone not only for Akero but for the entire NASH community,” said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. “As the fastest growing cause of liver transplantation and liver cancer in the US and Europe, NASH represents a substantial and growing health burden. We believe the data are very compelling and show EFX’s potential to meet the critical, global unmet need for patients by intervening across stages of disease progression, potentially addressing both early-stage metabolic drivers and later-stage inflammation and fibrosis.”

Summary of Week 24 Biopsy Endpoints

Measure (Mean) Placebo
(N=41) 28mg
(N=38) 50mg
(N=34)
Improvement in at least one stage of fibrosis without worsening NASH (%) 20 39 * 41 *
Resolution of NASH without worsening of fibrosis (%) 15 47 ** 76 ***
NASH resolution AND improvement in at least one stage of fibrosis (%) 5 29 ** 41 ***
* p<0.05, ** p<0.01, *** p<0.001, versus placebo (Cochran-Mantel-Haenszel test)
Biopsy scored independently by two pathologists; third available to adjudicate was not needed

Summary of Week 24 Changes in Liver Fat and Key Markers of Fibrosis and Liver Injury

Measure (LS Mean Change From Baseline to Week 24) Placebo
(N=40-42) 28mg
(N=35-38) 50mg
(N=34-36)
Hepatic Fat Fraction (MRI-PDFF) (%) -6 -52 *** -64 ***
ALT (%) -4 -38 *** -47 ***
AST (%) -2 -39 *** -49 ***
Pro-C3 (µg/L) +0.1 -5.1 *** -5.2 ***
ELF Score +0.1 -0.6 *** -0.7 ***
Liver Stiffness (kPa) (FibroScan) -0.7 -2.6 † -4.3 **
** p<0.01, *** p<0.001, versus placebo (ANCOVA [Fat Fraction, Liver Stiffness]; MMRM [other endpoints])
† p<0.05, versus baseline (MMRM)

Summary of Key Cardio-Metabolic Biomarkers

Measure (LS Mean Change From Baseline) Placebo
(N=42) 28mg
(N=35-37) 50mg
(N=35-36)
HbA1c (%, absolute) -0.0 -0.3 † -0.4 *
Triglycerides (%) +9 -25 *** -29 ***
HDL Cholesterol (%) -2 +24 *** +30 ***
Non-HDL Cholesterol (%) +8 -13 *** -13 ***
LDL Cholesterol (%) +9 -8 ** -8 **
Body Weight (kg) -0.6 -0.2 -2.9 ††
* p<0.05, ** p<0.01, *** p<0.001, versus placebo (MMRM)
† p<0.05, †† p<0.01, versus baseline (MMRM)

EFX was reported to be generally well tolerated. Across both dose groups, the most frequent adverse events (AEs) were grade 1 or 2 gastrointestinal events (diarrhea, nausea, increased appetite, and frequent bowel movements), which were transient in nature. A total of five patients treated with EFX were discontinued due to AEs (two in the 28mg group and three in the 50mg group, one of which was reported to be unrelated to study drug), compared with none for placebo. A single drug-related serious adverse event (SAE) of esophagitis was experienced by a patient in the 50mg group who had a history of gastroesophageal reflux disease. Three other SAEs were reported as unrelated to study drug.

In July of 2021, Akero initiated the SYMMETRY study, a Phase 2b trial in biopsy-confirmed NASH patients with compensated cirrhosis (F4), Child-Pugh class A. Based on enrollment to date, Akero expects to report results from the ongoing Phase 2b SYMMETRY study in the second half of 2023. Results from a 12-week expansion cohort of the SYMMETRY study, evaluating treatment of EFX on top of GLP-1 therapy in patients with F1-F3 fibrosis, are expected in the first half of 2023.

Conference Call / Webcast Details
Akero will host a conference call and webcast with slide presentation at 8:00 a.m. ET today. The live webcast will be available on the Events & Presentations page of the Akero website, with the recording and presentation available immediately following the event.

About NASH
NASH (non-alcoholic steatohepatitis) is a serious form of NAFLD (non-alcoholic fatty liver disease) that is estimated to affect 17 million Americans. NASH is characterized by an excessive accumulation of fat in the liver that causes stress and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death. There are no approved treatments for the condition and NASH is the fastest growing cause of liver transplants and liver cancer in the US and Europe.

About the HARMONY Study
The Phase 2b HARMONY study is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial in biopsy-confirmed adult NASH patients with fibrosis stage 2 or 3. The study enrolled a total of 128 patients, randomized to receive once-weekly subcutaneous dosing of 28mg or 50mg EFX, or placebo for 24-weeks. The primary efficacy endpoint for the study is the proportion of subjects who achieve at least a one-stage improvement in fibrosis without worsening of

1st post